Sana Biotechnology (SANA) EBIT (2020 - 2026)

Sana Biotechnology's EBIT history runs 7 years deep, the most recent figure standing at -$48.6 million for Q1 2026.

• In Q1 2026, EBIT rose 3.98% year-over-year to -$48.6 million; the TTM figure through Mar 2026 stood at -$248.3 million (down 16.78% YoY), while the FY2025 annual figure was -$250.3 million, up 8.21% from the prior year.
• EBIT came in at -$48.6 million for Q1 2026 at Sana Biotechnology, up from -$61.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$2.2 million in Q3 2023 to a low of -$116.3 million in Q2 2023.
• A 5-year average of -$66.9 million and a median of -$61.8 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT jumped 97.47% in 2023 and sank 2731.77% in 2024, its largest moves.
• Sana Biotechnology's EBIT stood at -$81.8 million in 2022, then declined by 10.8% to -$90.6 million in 2023, then soared by 43.87% to -$50.9 million in 2024, then slipped by 20.31% to -$61.2 million in 2025, then climbed by 20.56% to -$48.6 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$48.6 million, -$61.2 million, and -$43.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison